Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

NCT04086264 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04086264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04086264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 6, 2019
Completion date
February 28, 2027
Enrollment
218 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia